Novartis AG (NVS) Getting Somewhat Favorable News Coverage, Accern Reports
Press coverage about Novartis AG (NYSE:NVS) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novartis AG earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.2475187383336 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- FDA Advisory Committee Greenlights First Gene Therapy for Inherited Disorder (thestreet.com)
- Novartis AG (NVS) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Lilly’s (LLY) Verzenio Fails in Phase III Lung Cancer Study (finance.yahoo.com)
- Here Come More Gene Therapies — And More Pricing Debates (finance.yahoo.com)
- Novartis decides not to sell Roche stake chairman tells newspaper (finance.yahoo.com)
NVS has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research note on Tuesday, September 19th. Barclays PLC upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd. Cowen and Company set a $77.00 price target on shares of Novartis AG and gave the company a “hold” rating in a research note on Tuesday, July 11th. BidaskClub upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Leerink Swann restated a “market perform” rating and set a $83.00 price target on shares of Novartis AG in a research note on Thursday, June 22nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $84.13.
Shares of Novartis AG (NYSE:NVS) opened at 86.13 on Friday. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The firm’s 50-day moving average is $85.22 and its 200-day moving average is $81.80. The company has a market cap of $201.79 billion, a price-to-earnings ratio of 31.45 and a beta of 0.73.
Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. During the same period last year, the company earned $1.23 earnings per share. The company’s revenue was down 1.8% on a year-over-year basis. Equities research analysts predict that Novartis AG will post $4.75 earnings per share for the current year.
WARNING: “Novartis AG (NVS) Getting Somewhat Favorable News Coverage, Accern Reports” was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/novartis-ag-nvs-getting-somewhat-favorable-news-coverage-accern-reports/1629288.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.